Beam Therapeutics Inc. (BEAM) vs NeoGenomics, Inc. (NEO)
A side-by-side comparison of Beam Therapeutics Inc. and NeoGenomics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 2, 2026. Differences are shown without an overall score or investment verdict.
BEAM
Beam Therapeutics Inc.
$24.38HealthcareDelayed quote: Oct 2, 2026, 3:40 PM EDT
NEO
NeoGenomics, Inc.
$18.38HealthcareDelayed quote: Oct 2, 2026, 3:40 PM EDT
Total return — BEAM vs NEO
growth of $100 · dividends reinvested · last 7yBEAM +30.1% (+3.8%/yr)NEO -46.0% (-8.4%/yr)BEAM compounded faster over this window
BEAM NEO
BEAM vs NEO: by the numbers
- •BEAM is the larger company ($2.51B vs $472M market cap).
- •Both run net losses; NEO's is the smaller (-6.77% vs -54.75% net margin).
- •BEAM grew revenue faster over the past five years (479.04% vs 9.41% CAGR).
Metrics side by side
Valuation
| Metric | BEAM | NEO |
|---|---|---|
| Forward P/E | N/A | 100.61 |
| P/S ratio | 16.08 | 0.62 |
| P/B ratio | 2.35 | 0.60 |
Profitability
| Metric | BEAM | NEO |
|---|---|---|
| Gross margin | 84.05% | 42.92% |
| Operating margin | -274.57% | -8.63% |
| Net margin | -54.75% | -6.77% |
| ROE | -8.00% | -6.60% |
| ROIC | -28.96% | -5.29% |
Growth (annualized)
| Metric | BEAM | NEO |
|---|---|---|
| Revenue CAGR (5Y) | 479.04% | 9.41% |
| Total return CAGR (5Y) | -22.35% | -18.18% |
Frequently asked
- Which has grown faster, BEAM or NEO?
- Over the past five years, BEAM grew revenue faster — BEAM at a 479.04% CAGR versus NEO at 9.41%.
- How have BEAM and NEO total returns compared?
- Over the past 5 years, BEAM delivered -22.35% and NEO delivered -18.18% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Beam Therapeutics ROENeoGenomics ROEBeam Therapeutics operating marginNeoGenomics operating marginBeam Therapeutics revenue growthNeoGenomics revenue growthBeam Therapeutics free cash flowNeoGenomics free cash flow
Beam Therapeutics & NeoGenomics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 2, 2026.